Prostate carcinoma detection and increased prostate‐specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening

Ito, Kazuto; Raaijmakers, René; Roobol, Monique J.; Wildhagen, Mark F.; Yamanaka, Hidetoshi; Schröder, Fritz H.

doi:10.1002/cncr.20739

Cited by 24 publications

(27 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 A previous study compared the probability of freedom from PSA increases to levels greater than 4.0 ng/ml between Dutch and Japanese males. 35 Although there were statistically significant differences in mean PSA levels and the distribution of PSA levels between these two ethnic groups, the probability of PSA progression to greater than 4.0 ng/ml was not statistically significantly different between Dutch and Japanese males controlling for age and baseline PSA level. Our findings are similar in that despite finding differences in PSA levels between black and white males, the likelihood of conversion to PSA greater than 4.0 is not significantly different between the two ethnic groups.…”

Section: Discussionmentioning

confidence: 75%

Impact of race and baseline PSA on longitudinal PSA

McGreevy

Rodgers

Lipsitz

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

There is an increasing debate regarding the frequency of prostatespecific antigen (PSA) testing and the current primary screening modality used to detect prostate cancer. The purpose of this study is to determine whether PSA screening intervals should be based on initial PSA. Our study explores longitudinal changes of PSA levels in black and white males separately. Study participants were 768 white and 450 black males attending an annual prostate cancer screening. We fit a longitudinal repeated measures model separately for blacks and whites and estimated the probability of PSA converting to greater than 4.0 ng/ml at a follow-up year given baseline PSA range among males without an abnormal DRE. Black and white males with a baseline PSA between 0 and 1.0 ng/ml, with a healthy or enlarged prostate, have a less than 1% chance that their PSA will increase above 4.0 ng/ml over the following 5 years. Black and white males with a PSA between 1.0 and 1.9 ng/ml have a less than 1% chance of PSA conversion to greater than 4.0 ng/ml over the next year. Our findings further support that annual screening for prostate cancer may not be necessary, specifically males with a baseline PSA less than 2.0 may not need to undergo annual screening. Our results suggest that race does not affect the longitudinal trend of PSA enough to warrant setting screening intervals based on race. ' 2005 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 75%

Impact of race and baseline PSA on longitudinal PSA

McGreevy

Rodgers

Lipsitz

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…More recently, studies have shown that the baseline PSA level can predict the risk of developing prostate cancer, and one Japanese study showed that the baseline PSA levels in Japan from 1988 to 2003 remained stable over 16 years [8][9][10][11] . Therefore, we investigated the yearly changes in the baseline PSA levels in our hospital to determine the number of men with prostate cancer detected at periodic health exams at a health promotion center at our hospital from 1995 to 2008.…”

Section: Prostate Cancer In Koreamentioning

confidence: 99%

Prostate Cancer: Recent Trends in Korea

Hoon¹,

Chang²

2010

Urol Int

View full text Add to dashboard Cite

Introduction: We investigated the yearly changes in the baseline prostate-specific antigen (PSA) levels and the incidence of prostate cancer in men screened at our health promotion center from 1995 to 2008 to determine the trends in prostate cancer in Korea. Subjects and Methods: The participants were 6,007 men, who had PSA screening for the first time at the health promotion center. Changes in the baseline PSA levels, age, body mass index (BMI), and cholesterol levels were investigated. We evaluated the percentage of participants with a PSA level ≧2.0 and 4.0 ng/ml; the men were stratified by a 5-year age range, over two calendar years. In addition, we reviewed the results of their prostate biopsies. Results: The median baseline PSA level and the percentage of participants with a PSA level ≧2.0 and 4.0 ng/ml was not increased. The univariate and multivariate analyses, controlled for age and BMI, showed that two calendar years was not an independent predictive factor of the PSA level. The biopsy compliance rate increased from 36% during 1997–1998 to 70% during 2005–2006. Conclusions: The data from this study suggest that the increase in the incidence of prostate cancer might have been inaccurate in Korea.

show abstract

“…Third, the PC risk calculator used to estimate “RC‐based AIR” was based on data collected in European Randomized Study of Screening for Prostate Cancer (ERSPC) and may not be generalizable to the Japanese population. Most importantly, a previous international cooperative study of Dutch and Japanese men demonstrated that the risk for developing PC may be identical given similar baseline PSA levels . Furthermore, we performed a head to head comparison between our original predictive nomogram and the ERSPC nomogram using the same Japanese population data .…”

Section: Discussionmentioning

confidence: 99%

Long‐term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population‐based PSA screening

Oki

Ito

Suzuki

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Japan has experienced a drastic increase in the incidence of prostate cancer (PC). To assess changes in the risk for PC, we investigated baseline prostate specific antigen (PSA) levels in first-time screened men, across a 25-year period. In total, 72,654 men, aged 50-79, underwent first-time PSA screening in Gunma prefecture between 1992 and 2016. Changes in the distribution of PSA levels were investigated, including the percentage of men with a PSA above cut-off values and linear regression analyses comparing log PSA with age. The 'ultimate incidence' of PC and clinically significant PC (CSPC) were estimated using the PC risk calculator. Changes in the age-standardized incidence rate (AIR) during this period were analyzed. The calculated coefficients of linear regression for age versus log PSA fluctuated during the 25-year period, but no trend was observed. In addition, the percentage of men with a PSA above cut-off values varied in each 5-year period, with no specific trend. The 'risk calculator (RC)-based AIR' of PC and CSPC were stable between 1992 and 2016. Therefore, the baseline risk for developing PC has remained unchanged in the past 25 years, in Japan. The drastic increase in the incidence of PC, beginning around 2000, may be primarily due to increased PSA screening in the country.

show abstract

Prostate carcinoma detection and increased prostate‐specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening

Cited by 24 publications

References 7 publications

Impact of race and baseline PSA on longitudinal PSA

Impact of race and baseline PSA on longitudinal PSA

Prostate Cancer: Recent Trends in Korea

Long‐term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population‐based PSA screening

Contact Info

Product

Resources

About